Eliquis Demonstrates Superior Safety Profile Over Xarelto in Direct Comparison Trial for Venous Thrombosis
Key Insights
A head-to-head trial of 2,760 patients with venous thrombosis (search) found Eliquis (apixaban) caused significantly less clinically relevant bleeding than Xarelto (rivaroxaban) after three months of treatment.
The study showed 3.3% of Eliquis patients experienced bleeding complications compared to 7.1% of Xarelto patients, while both drugs demonstrated similar efficacy in preventing recurrent blood clots (search).
This New England Journal of Medicine study provides the first direct comparison evidence between these widely-used anticoagulants, offering physicians clearer guidance for treatment selection.
A landmark head-to-head trial comparing two of the most commonly prescribed blood-thinning medications has revealed that Eliquis (apixaban) carries a significantly lower risk of dangerous bleeding than Xarelto (rivaroxaban) in patients with deep vein blood clots (search), according to research published in The New England Journal of Medicine.
The randomized controlled trial enrolled 2,760 patients with venous thrombosis (search)—blood clots (search) in the veins of the legs or lungs—and directly compared the safety profiles of these two direct oral anticoagulants from the same drug class. After the standard three-month treatment course, 7.1% of participants taking Xarelto experienced clinically relevant bleeding, compared to just 3.3% of those receiving Eliquis.
Clinical Significance for Patient Care
"This trial provides highly anticipated evidence for physicians and should bring real peace of mind to venous thrombosis (search) patients, who often live with the dual fear of blood clot recurrence and bleeding," said study leader Dr. Lana Castellucci of The Ottawa Hospital in Canada.
The study found no apparent difference in the risk of recurrent blood clots (search) between the two medications, suggesting both drugs maintain their intended therapeutic purpose. However, researchers noted that the study population wasn't large enough to allow reliable detection of true differences in efficacy outcomes.
Drug Performance and Market Impact
Eliquis, manufactured by Bristol Myers Squibb (search) and Pfizer, and Xarelto, produced by Bayer (search) and Johnson & Johnson, are both prescribed to prevent recurrent blood clots (search) that can lead to strokes. While these anticoagulants are effective at preventing clot formation, they can sometimes cause serious bleeding episodes—a critical safety concern for both patients and physicians.
Study Limitations and Broader Implications
The research involved primarily white patients with healthy kidneys and livers, without cancer or obesity, which may limit the generalizability of results to more diverse patient populations. Despite these constraints, the findings provide crucial evidence for clinical decision-making.
"Despite these limitations, the trial provides vital evidence for the treatment of venous thromboembolism (search)," wrote Dr. Lisa Moores of the Uniformed Services University of the Health Sciences in Bethesda, Maryland, in an accompanying NEJM editorial. "Apixaban is a safer first-line option than rivaroxaban for minimizing the risk of bleeding without compromising the prevention of recurrent thrombosis."
Clinical Practice Implications
The study represents the first direct comparison between these two widely-used anticoagulants, filling a significant evidence gap in clinical practice. Previously, physicians had to rely on indirect comparisons and individual drug studies when selecting between these treatment options.
The research provides physicians with concrete data to guide treatment decisions, particularly for patients at higher risk of bleeding complications. The substantial difference in bleeding rates—more than double the risk with Xarelto compared to Eliquis—offers clear clinical guidance for anticoagulation therapy selection in venous thromboembolism (search) treatment.